PURPOSE: We previously reported that all-trans retinoic acid (ATRA) inhibited growth in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and in fresh cells from patients with adult T cell leukemia (ATL). Here, we confirmed the clinical effects of ATRA in 20 patients with ATL. MATERIALS AND METHODS: The 20 patients (n = 20) with a median age of 56 (range 35-73) years who were diagnosed with ATL received ATRA orally. RESULTS: The efficacy of treatment was as follows: no complete response (CR), a partial response (PR) in 40% of the patients, no change (NC) in 45% of the patients, and a progressive disease (PD) in 15% of the patients. In seven acute-type ATL patients, a PR was achieved in two (28.5%), NC was observed in two (28.5%), and a PD was observed in three (42.8%). In three lymphoma-type ATL patients, a PR (100%) was achieved. Among four chronic-type ATL patients, a PR was achieved in one (25%) and NC was observed in the remaining three (75%). In six smoldering-type ATL patients, a PR was achieved in two (33.3%) and NC was observed in four (66.6%). The major side effects were headache (n = 5), transient liver dysfunction (n = 2), hyperlipidemia (n = 2), and anorexia (n = 1). CONCLUSION: These results indicated that ATRA might be a useful agent for the safe treatment of ATL.
PURPOSE: We previously reported that all-trans retinoic acid (ATRA) inhibited growth in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and in fresh cells from patients with adult T cell leukemia (ATL). Here, we confirmed the clinical effects of ATRA in 20 patients with ATL. MATERIALS AND METHODS: The 20 patients (n = 20) with a median age of 56 (range 35-73) years who were diagnosed with ATL received ATRA orally. RESULTS: The efficacy of treatment was as follows: no complete response (CR), a partial response (PR) in 40% of the patients, no change (NC) in 45% of the patients, and a progressive disease (PD) in 15% of the patients. In seven acute-type ATL patients, a PR was achieved in two (28.5%), NC was observed in two (28.5%), and a PD was observed in three (42.8%). In three lymphoma-type ATLpatients, a PR (100%) was achieved. Among four chronic-type ATL patients, a PR was achieved in one (25%) and NC was observed in the remaining three (75%). In six smoldering-type ATL patients, a PR was achieved in two (33.3%) and NC was observed in four (66.6%). The major side effects were headache (n = 5), transient liver dysfunction (n = 2), hyperlipidemia (n = 2), and anorexia (n = 1). CONCLUSION: These results indicated that ATRA might be a useful agent for the safe treatment of ATL.
Authors: R Sobue; T Yamauchim; K Miyamura; H Sao; T Tahara; H Yoshikawa; S Yoshikawa; Y Morishima; Y Kodera Journal: Bone Marrow Transplant Date: 1987-12 Impact factor: 5.483
Authors: Y Yamada; M Tomonaga; H Fukuda; S Hanada; A Utsunomiya; M Tara; M Sano; S Ikeda; K Takatsuki; M Kozuru; K Araki; F Kawano; M Niimi; K Tobinai; T Hotta; M Shimoyama Journal: Br J Haematol Date: 2001-05 Impact factor: 6.998
Authors: B Rio; C Louvet; A Gessain; D Dormont; C Gisselbrecht; R Martoia; G Auzanneau; J M Miclea; E Baumelou; H Dombret Journal: Presse Med Date: 1990-04-21 Impact factor: 1.228
Authors: P Ljungman; M Lawler; B Asjö; G Bogdanovic; K Karlsson; C Malm; S R McCann; O Ringdén; G Gahrton Journal: Br J Haematol Date: 1994-10 Impact factor: 6.998
Authors: H Taguchi; K I Kinoshita; K Takatsuki; M Tomonaga; K Araki; N Arima; S Ikeda; K Uozumi; H Kohno; F Kawano; H Kikuchi; H Takahashi; K Tamura; S Chiyoda; H Tsuda; H Nishimura; T Hosokawa; H Matsuzaki; S Momita; O Yamada; I Miyoshi Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-06-01
Authors: Xueju Wang; Surendra Dasari; Grzegorz S Nowakowski; Konstantinos N Lazaridis; Eric D Wieben; Marshall E Kadin; Andrew L Feldman; Rebecca L Boddicker Journal: Oncotarget Date: 2017-04-18